Expected 12-week outcome with AOD-9604: approximately 7-8.5 kg total weight loss, roughly 5.5-6.5 kg from fat, 1-2 kg from lean tissue and water
Compound Receptors Peak trial weight loss Lean mass as share of loss Semaglutide (Ozempic/Wegovy) GLP-1 ~14.9% (STEP-1, 68 wk) ~39% Tirzepatide (Mounjaro/Zepbound) GLP-1 + GIP ~20.9% (SURMOUNT-1, 72 wk) ~25-40% Retatrutide GLP-1 + GIP + GCGR ~24.2% (Phase 2, 48 wk) Comparable class range Best for understanding the takeaway: the percentage of loss that is lean mass is roughly constant across the class
When in reality, MOTS-c and 5-Amino-1MQ address metabolic dysfunction through distinct, non-overlapping biological mechanisms
The difference between what patients experience at Perfect B and what they report from self-administration online is not the peptide itself
This narrow therapeutic window means dosing precision matters more for KPV research than for peptides with broader dose-response curves
Review the dosing selection guide for personalized recommendations